Chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease, unspecified
Conditions
Interventions
Intervention 1: Moderate-intensity parallel exercise intervention group: Participants in this group will participate in a moderate-intensity parallel exercise program, 3 sessions per week for 8 weeks.
Sponsors
Hakim Sabzevari University
Eligibility
Sex/Gender
Male
Age
40 Years to 70 Years
Inclusion criteria
Inclusion criteria: Men with chronic obstructive pulmonary disease FEV1/FVC ratio less than 0.7 Stable clinical condition for at least four weeks No acute exacerbation or hospitalization within the past month Lack of participation in structured exercise programs in the past three to six months Active exacerbation of the disease or need for systemic corticosteroids Age range between 40-70 years
Exclusion criteria
Exclusion criteria: Presence of concomitant cardiovascular, metabolic, or neuromuscular diseases Musculoskeletal or orthopedic problems that prevent physical activity Active exacerbation of the disease or need for systemic corticosteroids Use of medications or interventions that interfere with athletic performance, such as nonsteroidal anti-inflammatory drugs, injectable, inhaled, and oral corticosteroids, and immunomodulatory drugs Failure to adhere to the study protocol and failure to attend three consecutive practice sessions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Forced Expiratory Volume in 1 Second. Timepoint: Before the start of the study and after eight weeks of training 4 hours after the last training session. Method of measurement: In a standing position, the spirometer mouthpiece is placed in the mouth so that the lips completely cover the mouthpiece. Finally, after a deep breath, they empty the air in the lungs with all the pressure. For each stage, each subject will perform the spirometry test three times and we will consider the best performance.;Transforming growth factor beta. Timepoint: Before the start of the study and 4 hours after the last training session. Method of measurement: A 5 ml of venous blood will be taken from each subject from the antecubital vein by a laboratory technician under strict aseptic conditions. The samples will be collected in tubes without anticoagulant (Serum Tube) and placed at room temperature for 10-15 minutes to complete the clotting process. After the clot is formed, the tubes will be placed in a centrifuge for 10 minutes at a speed of 360 rpm. At the end of the centrifugation, the clear and yellowish upper part of the sample, known as serum, will be gently separated using a sterile sampler and transferred to Eppendorf microtubes and then measured using the relevant laboratory kit.;Matrix metalloproteinase-2. Timepoint: Before the start of the study and 4 hours after the last training session. Method of measurement: A 5 ml of venous blood will be taken from each subject from the antecubital vein by a laboratory technician under strict aseptic conditions. The samples will be collected in tubes without anticoagulant (Serum Tube) and placed at room temperature for 10-15 minutes to complete the clotting process. After the clot is formed, the tubes will be placed in a centrifuge for 10 minutes at a speed of 360 rpm. At the end of the centrifugation, the clear and yellowish upper part of the sample, known as serum, will be gently separated using a sterile sampler and transferred to Epp | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete blood count. Timepoint: Before the start of the study and 48 hours after the last training session. Method of measurement: A 5 ml of venous blood will be taken from each subject from the antecubital vein by a laboratory technician under strict aseptic conditions. The samples will be collected in tubes without anticoagulant (Serum Tube) and placed at room temperature for 10-15 minutes to complete the clotting process. After the clot is formed, the tubes will be placed in a centrifuge for 10 minutes at a speed of 360 rpm. At the end of the centrifugation, the clear and yellowish upper part of the sample, as serum, will be gently separated using a sterile sampler and transferred to Eppendorf microtubes and then measured using the relevant laboratory kits. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmirhossein Mohkami
Hakim Sabzevari University
Outcome results
None listed